Breaking News, Collaborations & Alliances

SHINE and Telix Pharmaceuticals Enter Clinical Supply Agreement

SHINE to supply n.c.a. Lu-177 for the clinical development of Telix’s investigational radiopharmaceuticals, TLX591 and TLX250.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

SHINE Technologies, a next-generation nuclear technology company, and Telix Pharmaceuticals, a biopharmaceutical company headquartered in Australia, have signed a clinical supply agreement that provides Telix with SHINE’s non-carrier-added (n.c.a.) lutetium-177 (Lu-177) for use in the clinical development of potential new therapeutics to treat prostate and kidney cancer. SHINE will immediately commence supply of n.c.a. Lu-177 for use in clinical trials of Telix’s therapeutic candidates TLX591...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters